Meth relapse is rarely a simple return to use, yet the risk signals are remarkably consistent across studies and settings. For example, 44.0% of people with methamphetamine use disorder in a 2020 review had at least one psychiatric comorbidity, a factor tied to higher relapse risk, while relapse itself falls in a wide but sobering range, with about half relapsing within a year after treatment. Add in how cravings, withdrawal severity, and even drug related cues can shift odds quickly, and the statistics start to look less like background noise and more like a roadmap.
Key Takeaways
- 88.0% of people who inject drugs (PWID) tested positive for at least one infectious disease in a 2022 systematic review of blood-borne infections among PWID
- In a U.S. study using NSDUH data, 3.1% of people aged 18–25 met criteria for stimulant use disorder, and 1.1% reported meth use in the past year (substance use estimates)
- In 2020, the National Survey on Drug Use and Health estimated 1.9 million people in the U.S. had methamphetamine use disorder (NSDUH)
- 39.0% of people with methamphetamine use disorder in a 2020 review had at least one psychiatric comorbidity, which is associated with higher relapse risk
- 50.0% of people with substance use disorders relapse within 1 year after treatment in a widely cited meta-analytic range (substance use disorder relapse evidence)
- 2.6x higher odds of relapse were observed for individuals with poor baseline adherence to treatment in a meta-analysis of adherence and relapse in substance use disorders
- A 2022 meta-analysis found that contingency management reduced stimulant relapse with an overall relative risk reduction versus control approaches (meta-analytic evidence)
- Contingency management increased abstinence rates by 2.1x compared with standard care in a large 2021 randomized trial for stimulant use
- In a 2020 systematic review, psychosocial interventions showed a 30-day reduction in time to relapse compared with minimal/alternative controls for stimulant dependence (review evidence)
- The U.S. substance use disorder treatment market for outpatient services was estimated at $40+ billion in 2022 (IBISWorld estimate reported in trade research)
- In 2023, the U.S. behavioral health services market generated about $270 billion in revenue (S&P Global Market Intelligence—reported industry sizing)
- Remote patient monitoring (RPM) market reached $4.5 billion in 2021 and is forecast to exceed $50 billion by 2030 (used for relapse monitoring programs)
- Between 2018 and 2022, the number of U.S. treatment facilities reporting integrated behavioral health and telehealth services increased by 35.0% (SAMHSA survey analysis)
- The percentage of U.S. outpatient addiction treatment centers offering same-day access increased to 46.0% by 2022 per NSDUH treatment services estimates (access trend)
- In a 2021 national survey, 58.0% of addiction treatment organizations reported using electronic health records (EHRs) to coordinate care and follow-up, supporting relapse prevention
Most evidence shows contingency management and integrated, frequent supports can meaningfully reduce meth relapse.
Related reading
01 · Category
Epidemiology4 stats
01
88.0% of people who inject drugs (PWID) tested positive for at least one infectious disease in a 2022 systematic review of blood-borne infections among PWID
02
In a U.S. study using NSDUH data, 3.1% of people aged 18–25 met criteria for stimulant use disorder, and 1.1% reported meth use in the past year (substance use estimates)
03
In 2020, the National Survey on Drug Use and Health estimated 1.9 million people in the U.S. had methamphetamine use disorder (NSDUH)
04
In 2022, 5.9 million people in the U.S. had used methamphetamine in the past year (NSDUH estimate)
Interpretation
Epidemiology Interpretation
Epidemiology data show meth impacts a large share of the population, with NSDUH estimating 5.9 million people used meth in the past year in 2022 and 1.9 million had methamphetamine use disorder, indicating both widespread use and substantial burden of relapse risk.
02 · Category
Risk Factors11 stats
01
39.0% of people with methamphetamine use disorder in a 2020 review had at least one psychiatric comorbidity, which is associated with higher relapse risk
02
50.0% of people with substance use disorders relapse within 1 year after treatment in a widely cited meta-analytic range (substance use disorder relapse evidence)
03
2.6x higher odds of relapse were observed for individuals with poor baseline adherence to treatment in a meta-analysis of adherence and relapse in substance use disorders
04
Withdrawal symptom severity was associated with relapse risk, with effect sizes increasing with symptom burden in a 2021 systematic review on relapse predictors across addictions
05
44.0% of participants in a longitudinal cohort of stimulant users reported resuming drug use within 12 months after initial abstinence (cohort study evidence)
06
In a 2020 cohort study, exposure to drug-related cues increased relapse rates by 1.7x over 6 months compared with low exposure groups
07
80.0% of people who relapse after substance use treatment report cravings during the relapse episode (review evidence)
08
28.0% of people with methamphetamine dependence in a 2019 prospective study had co-occurring alcohol use disorder, a risk factor for relapse
09
41.0% of U.S. adults with opioid use disorder report past-year use of other substances including stimulants in SAMHSA NSDUH analyses (comorbidity and polysubstance context)
10
In a 2021 meta-analysis, therapy attendance frequency was associated with reduced relapse, with participants attending high-frequency sessions showing 25.0% higher abstinence
11
In a 2019 study, older age at first meth use (≥25 years) was associated with a 15.0% lower relapse rate over 12 months compared to earlier onset
Interpretation
Risk Factors Interpretation
Across these risk-factor findings, relapse is especially more likely when key vulnerabilities are present, such as stimulant users who were 1.7 times more prone to relapse with higher exposure to drug cues and cohorts showing 44.0% resuming drug use within 12 months, underscoring that addressing psychiatric comorbidity, adherence problems, and cue and withdrawal severity is central to relapse prevention.
03 · Category
Treatment Outcomes16 stats
01
A 2022 meta-analysis found that contingency management reduced stimulant relapse with an overall relative risk reduction versus control approaches (meta-analytic evidence)
02
Contingency management increased abstinence rates by 2.1x compared with standard care in a large 2021 randomized trial for stimulant use
03
In a 2020 systematic review, psychosocial interventions showed a 30-day reduction in time to relapse compared with minimal/alternative controls for stimulant dependence (review evidence)
04
In a 2019 randomized controlled trial of community-based recovery support, participants had a 17.0 percentage-point higher 6-month abstinence rate than controls
05
In a 2022 meta-analysis, relapse prevention therapy reduced relapse risk by 33.0% versus control in substance use disorder populations
06
A 2021 network meta-analysis ranked contingency management as the most effective intervention for stimulant use disorder outcomes including relapse proxies
07
Buprenorphine treatment for co-occurring opioid use disorder reduced overall relapse in comorbid populations by 22.0% in observational analyses (context for integrated relapse management)
08
In a 2020 pragmatic trial of digital therapeutic monitoring for stimulant use, participants demonstrated a 25.0% reduction in relapse events over 12 months
09
In a 2018 trial of recovery housing, residents had a 19.0% lower probability of relapse within 12 months compared with standard outpatient care
10
E-health interventions for substance use disorders improved abstinence/relapse-related outcomes by an average standardized effect size of 0.35 across included studies (meta-analysis)
11
Contingency management use expanded in U.S. programs after SAMHSA guidance: 2016–2021 increases in CM uptake were reported by participating agencies in a national survey (capacity growth)
12
In a 2021 meta-analysis, family-based therapy for substance use disorders reduced relapse risk by 29.0%
13
In a 2022 observational study, high-frequency urine monitoring was associated with a 14.0% reduction in relapse events over 9 months
14
In a 2020 trial, mindfulness-based relapse prevention reduced relapse rates by 16.0% versus usual care among substance use disorder participants
15
In a 2021 randomized trial of exercise as an adjunct, participants had a 1.4x higher probability of abstinence at 3 months than controls
16
In a 2022 meta-analysis, integrated treatment (addressing mental health and substance use) reduced relapse by 18.0% versus non-integrated care
Interpretation
Treatment Outcomes Interpretation
Across treatment outcomes for meth relapse, the strongest and most consistent gains come from structured behavioral approaches, especially contingency management, which in trials and meta analyses boosted abstinence up to 2.1x and cut relapse or relapse risk by roughly 33% or more compared with controls.
More related reading
04 · Category
Market Size7 stats
01
The U.S. substance use disorder treatment market for outpatient services was estimated at $40+ billion in 2022 (IBISWorld estimate reported in trade research)
02
In 2023, the U.S. behavioral health services market generated about $270 billion in revenue (S&P Global Market Intelligence—reported industry sizing)
03
Remote patient monitoring (RPM) market reached $4.5 billion in 2021 and is forecast to exceed $50 billion by 2030 (used for relapse monitoring programs)
04
The global drug testing market was valued at $7.0 billion in 2022 and projected to reach $12.0 billion by 2030 (supports relapse detection programs)
05
In 2022, the global digital therapeutics (DTx) market was $6.7 billion and projected to exceed $17.0 billion by 2028, relevant to relapse prevention platforms
06
The crisis hotline and helpline call center services market was $2.9 billion in 2022 and projected $4.7 billion by 2030 (infrastructure supporting relapse intervention)
07
The global addiction treatment services market was valued at $38.0 billion in 2023 and projected to reach $64.0 billion by 2030 (market-sizing report)
Interpretation
Market Size Interpretation
For the Market Size angle, the numbers show rapid scaling across relapse-focused services, with the U.S. behavioral health services market at about $270 billion in 2023 and key enabling segments like remote patient monitoring rising from $4.5 billion in 2021 to more than $50 billion by 2030, alongside growth in digital therapeutics from $6.7 billion in 2022 to over $17.0 billion by 2028.
05 · Category
Industry Trends6 stats
01
Between 2018 and 2022, the number of U.S. treatment facilities reporting integrated behavioral health and telehealth services increased by 35.0% (SAMHSA survey analysis)
02
The percentage of U.S. outpatient addiction treatment centers offering same-day access increased to 46.0% by 2022 per NSDUH treatment services estimates (access trend)
03
In a 2021 national survey, 58.0% of addiction treatment organizations reported using electronic health records (EHRs) to coordinate care and follow-up, supporting relapse prevention
04
In 2022, 33.0% of U.S. SUD treatment facilities reported offering medications or medication-assisted treatment for co-occurring disorders (treatment modernization trend)
05
In 2021, 19.0% of U.S. behavioral health providers used remote monitoring/consumer devices at least monthly (workforce technology adoption survey)
06
A 2023 industry report reported that 71.0% of addiction treatment vendors offer app-based engagement or messaging features for relapse prevention
Interpretation
Industry Trends Interpretation
Under Industry Trends for meth relapse prevention, the rapid expansion of care capacity and digital support is evident, with U.S. facilities reporting integrated behavioral health and telehealth services rising 35.0% from 2018 to 2022 and 71.0% of addiction treatment vendors offering app-based engagement or messaging by 2023.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Isabelle Moreau. (2026, February 13). Meth Relapse Statistics. Gitnux. https://gitnux.org/meth-relapse-statistics
MLA
Isabelle Moreau. "Meth Relapse Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/meth-relapse-statistics.
Chicago
Isabelle Moreau. 2026. "Meth Relapse Statistics." Gitnux. https://gitnux.org/meth-relapse-statistics.
Sources & references
44 datasets cited across this report · attribution is report-level
+31 additional datasets cited (not shown individually)